News & Events
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis (opens in a new tab)
– SER-301 is designed to target the physiological triggers of inflammation believed to be central to the underlying pathology of ulcerative colitis – – Program represents Seres’ second active clinical program targeting ulcerative colitis, in addition to its ongoing SER-287 Phase 2b study –…
Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 2, 2020– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that…
Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 22, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege , Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M.…
Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020 (opens in a new tab)
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scie…
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting (opens in a new tab)
– New data demonstrate a sustained patient benefit following SER-109 administration with a highly statistically significant 31.1% absolute reduction in the rate of C. difficile infection recurrence over 12 weeks, compared to placebo – – Additional new findings show similar SER-109 efficacy across…
Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020 (opens in a new tab)
Phase 1 development partner Janssen to present data showing VE202 microbiome-derived bacterial strains rapidly, abundantly and durably colonize the gut of healthy volunteers CAMBRIDGE, Mass., October 12, 2020 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-media…
Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients (opens in a new tab)
Award is first-ever by BARDA directed to advance development of a microbiome drug CAMBRIDGE, Mass., September 30, 2020 – Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today ann…
Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 22, 2020– Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday, September 23 at 8:00 a.m. E.T.…
Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer (opens in a new tab)
Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins leadership team as vice president of legal Company also secured $15 million from Oxford Finance to further support pipeline development CAMBRIDGE, Mass., September 16, 2020 – Vedanta Biosciences, a leading clinical-stage company developing a new category of ther…
Seres Therapeutics to Present at Upcoming Investor Conferences (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 14, 2020– Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences: H.C. Wainwright 22nd Annual Global Investment Conference : Seres will present a corporate overview on Wednesday, September…
Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 11, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License…
Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 17, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat…
Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 12, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat…
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection (opens in a new tab)
– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo – – SER-109 was well tolerated, with a safety profile comparable to placebo – – Efficacy results substantially exceeded…
Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates (opens in a new tab)
– Topline data from SER-109 Phase 3 study in recurrent C. difficile infection expected in August 2020 ; Potential to be the single pivotal study supporting FDA product registration – – Company continues to advance multiple additional clinical-stage microbiome therapeutic programs, including…
Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer (opens in a new tab)
– Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres’ microbiome therapeutic pipeline – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 22, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young…
Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD) (opens in a new tab)
VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonization that will inform the Phase 2 dose regimen Vedanta has regained full rights to the program and plans to advance it in a Phase 2 study within the next 12 months Company also announces the issuance of three Euro…
Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 2, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41 st Annual Global Virtual Healthcare Conference on Tuesday, June 9 th at 2:10 p.m. ET .…
Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 28, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET . A live audio webcast of the presentation will be available…
Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out (opens in a new tab)
– Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020 – CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 18, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual webcast symposium focused on SER-109 as a potential new therapeutic option…